13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802630
Total reported value
$2.9B
$2.9B
75 檔
16.5%
In Q1 2025, Soleus Capital Management, L.P.'s U.S. equity holdings reached a combined market value of $2.9B, distributed across 75 disclosed stock positions.
In Q1 2025, Soleus Capital Management, L.P. displayed an active expansion posture, initiating 50 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 8.17% | — | -53.33% | |
| 2 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 8.08% | +0.12% | +6.17% | |
| 3 | NVCR | NovoCure Limited | Stock-Healthcare | 7.08% | +0.55% | +101.53% | |
| 4 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 5.73% | -0.03% | +23.27% | |
| 5 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 5.49% | -0.75% | +7.78% | |
| 6 | ORGO | Organogenesis Holdings Inc | Stock-Other | 3.88% | -0.12% | -0.05% | |
| 7 | GRFS | Grifols Sa-adr | Stock-Other | 3.63% | — | +7.33% | |
| 8 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.45% | -0.29% | +42.05% | |
| 9 | STAA | Staar Surgical Co | Stock-Other | 3.25% | -0.02% | EXIT | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.11% | -2.26% | +367.99% | |
| 11 | BBNX | Beta Bionics Inc | Stock-Other | 2.99% | +0.60% | — | |
| 12 | NPCE | Neuropace Inc | Stock-Other | 2.31% | +0.03% | +7.19% | |
| 13 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.07% | +0.63% | +15.22% | |
| 14 | AXGN | Axogen Inc | Stock-Other | 1.93% | -0.82% | -51.08% | |
| 15 | CELC | Celcuity Inc | Stock-Other | 1.87% | +0.20% | +0.35% | |
| 16 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 1.87% | -0.12% | +18.67% | |
| 17 | SU6 | Surmodics Inc | Stock-Other | 1.73% | — | +100.24% | |
| 18 | IART | Integra Lifesciences Holding | Stock-Other | 1.70% | — | -15.97% | |
| 19 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.62% | — | +0.30% | |
| 20 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.61% | — | +519.27% | |
| 21 | INSM | Insmed Inc | Stock-Healthcare | 1.51% | +0.26% | -14.36% | |
| 22 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 1.46% | +2.48% | — | |
| 23 | HO1 | Hologic Inc | Stock-Other | 1.34% | — | — | |
| 24 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.23% | +0.54% | — | |
| 25 | ✓ | Merus N V | Stock-Other | 1.17% | — | +23.53% | |
| 26 | NUVL | Nuvalent Inc-a | Stock-Other | 1.09% | — | +105.41% | |
| 27 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.08% | -0.07% | +9.45% | |
| 28 | FOCL | Edap Tms SA -adr | Stock-Other | 1.03% | +0.20% | — | |
| 29 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.00% | +0.02% | — | |
| 30 | EOLS | Evolus Inc | Stock-Other | 0.93% | -0.17% | +54.79% | |
| 31 | PHVS | Pharvaris N.V. | Stock-Other | 0.92% | +0.07% | — | |
| 32 | SNY | Sanofi-adr | Stock-Healthcare | 0.90% | — | — | |
| 33 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.80% | +0.13% | — | |
| 34 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.77% | — | — | |
| 35 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.75% | -0.48% | — | |
| 36 | ACLXGBX | Arcellx Inc | Stock-Other | 0.72% | — | +26.44% | |
| 37 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.72% | -0.40% | -67.23% | |
| 38 | OFIX | Orthofix Medical Inc | Stock-Other | 0.71% | — | -12.30% | |
| 39 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 0.68% | -0.31% | — | |
| 40 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.66% | — | +70.11% | |
| 41 | ASND | Ascendis Pharma A/S | Stock-Other | 0.63% | — | -60.90% | |
| 42 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.59% | — | -38.55% | |
| 43 | VTLUSD | Immunic Inc | Stock-Other | 0.57% | -0.20% | EXIT | |
| 44 | CGON | Cg Oncology Inc | Stock-Other | 0.54% | -0.04% | -7.61% | |
| 45 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.50% | — | -78.48% | |
| 46 | TQ80 | Theratechnologies Inc | Stock-Other | 0.48% | — | — | |
| 47 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.46% | -0.01% | EXIT | |
| 48 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.45% | +1.77% | — | |
| 49 | VSTM | Verastem Inc | Stock-Other | 0.41% | — | -57.15% | |
| 50 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.34% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 2 | TGTX | Tg Therapeutics Inc | — | NEW | New buy |
| 3 | NVCR | NovoCure Limited | — | NEW | New buy |
| 4 | KRYS | Krystal Biotech Inc | — | NEW | New buy |
| 5 | BMRN | Biomarin Pharmaceutical Inc | — | NEW | New buy |
| 6 | ORGO | Organogenesis Holdings Inc | — | NEW | New buy |
| 7 | GRFS | Grifols Sa-adr | — | NEW | New buy |
| 8 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 9 | STAA | Staar Surgical Co | — | NEW | New buy |
| 10 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 11 | BBNX | Beta Bionics Inc | — | NEW | New buy |
| 12 | NPCE | Neuropace Inc | — | NEW | New buy |
| 13 | NRIX | Nurix Therapeutics Inc | — | NEW | New buy |
| 14 | AXGN | Axogen Inc | — | NEW | New buy |
| 15 | CELC | Celcuity Inc | — | NEW | New buy |
| 16 | IOVA | Iovance Biotherapeutics Inc | — | NEW | New buy |
| 17 | SU6 | Surmodics Inc | — | NEW | New buy |
| 18 | IART | Integra Lifesciences Holding | — | NEW | New buy |
| 19 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 20 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 21 | INSM | Insmed Inc | — | NEW | New buy |
| 22 | RIGL | Rigel Pharmaceuticals Inc | — | NEW | New buy |
| 23 | HO1 | Hologic Inc | — | NEW | New buy |
| 24 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 25 | ✓ | Merus N V | — | NEW | New buy |
| 26 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 27 | ANIP | Ani Pharmaceuticals Inc | — | NEW | New buy |
| 28 | FOCL | Edap Tms SA -adr | — | NEW | New buy |
| 29 | IKT | Inhibikase Therapeutics Inc | — | NEW | New buy |
| 30 | EOLS | Evolus Inc | — | NEW | New buy |
| 31 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 32 | SNY | Sanofi-adr | — | NEW | New buy |
| 33 | CCCC | C4 Therapeutics Inc | — | NEW | New buy |
| 34 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 35 | KNSA | Kiniksa Pharmaceuticals International, plc | — | NEW | New buy |
| 36 | ACLXGBX | Arcellx Inc | — | NEW | New buy |
| 37 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 38 | OFIX | Orthofix Medical Inc | — | NEW | New buy |
| 39 | TNDM | Tandem Diabetes Care Inc | — | NEW | New buy |
| 40 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 41 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 42 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 43 | VTLUSD | Immunic Inc | — | NEW | New buy |
| 44 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 45 | TEVA | Teva Pharmaceutical-sp Adr | — | NEW | New buy |
| 46 | TQ80 | Theratechnologies Inc | — | NEW | New buy |
| 47 | JSPR | Jasper Therapeutics Inc | — | NEW | New buy |
| 48 | INSP | Inspire Medical Systems Inc | — | NEW | New buy |
| 49 | VSTM | Verastem Inc | — | NEW | New buy |
| 50 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Soleus Capital Management, L.P. reported a total U.S. public equity portfolio value of $2.9B across 75 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, TGTX, NVCR) accounted for 16.5% of total reported equity market value during Q1 2025.
Top New Position Initiated
XBI
市值: $113.5M
During Q1 2025, Soleus Capital Management, L.P.'s top holdings by market value included XBI (8.2%)、TGTX (8.1%)、NVCR (7.1%). The largest single position, XBI, represented 8.2% of total portfolio value.
In Q1 2025, Soleus Capital Management, L.P. made 50 total portfolio adjustments, initiating 50 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.